LIPELLA PHARMACEUTICALS INC (LIPO) Stock Income Statement
NASDAQ:LIPO - Nasdaq - US53630L2097 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 519.90K | 536.40K | 449.60K | 184.20K | 259.40K | |||
| Operating Expenses | 5.71M | 5.62M | 5.20M | 2.77M | 2.18M | |||
| Research and Development | 3.76M | 3.61M | 3.04M | 2.55M | 1.46M | |||
| Selling, General, and Administrative Expenses | 1.95M | 2.00M | 2.16M | 226.20K | 718.40K | |||
| Operating Income | -5.19M | -5.08M | -4.75M | -2.59M | -1.92M | |||
| Interest Income/Expense | 59.70K | 64.30K | 127.00K | -7.90K | -6.70K | |||
| Other Income/Expense | N/A | N/A | 0.00 | -100.00 | 57.10K | |||
| Income Before Taxes | -5.13M | -5.02M | -4.62M | -2.60M | -1.87M | |||
| Income Tax | N/A | N/A | N/A | 0.00 | 0.00 | |||
| Net Income | -5.13M | -5.02M | -4.62M | -2.60M | -1.87M | |||
| EBITDA | -5.19M | -5.08M | -4.74M | N/A | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -4.10 | -4.79 | -6.16 | -5.12 | -2.60 | |||
| Statistics | ||||||||
| Profit Margin | -986.92% | -935.18% | -1027.36% | -1410.26% | -719.16% | |||
| Operating Profit Margin | -998.40% | -947.15% | -1055.60% | -1405.92% | -738.55% | |||
All data in USD